Disease · MONDO_0005328

eye disorder

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. eye disorder. Diseases, record MONDO_0005328. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0005328

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: eye disorder; Open Targets
Open Targets ID: MONDO_0005328; Open Targets
Other names: disease of eye, disease of eyeball of camera-type eye, disease or disorder of eyeball of camera-type eye, disorder of eye, disorder of eyeball of camera-type eye, eye disease, eyeball of camera-type eye disease, eyeball of camera-type eye disease or disorder, globe disease; Open Targets
Disease Ontology: DOID:1242; Disease Ontology
Disease Ontology: DOID:5614; Disease Ontology
MeSH: D005128; MeSH
NCI Thesaurus: C26767; NCI Thesaurus
Highest stage of its drugs: Approval, for 26 of its 50 drugs, from ATC; Open Targets

Drugs50

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
CYCLOSPORINE	CHEMBL160	Protein	Approval	ATC	3	2	2	Drugs and targets
OCRIPLASMIN	CHEMBL2095222	Protein	Approval	ATC	2	0	0	Drugs and targets
ACETYLCYSTEINE	CHEMBL600	Small molecule	Approval	ATC	1	0	0	Drugs and targets
ALTEPLASE	CHEMBL1201593	Enzyme	Approval	ATC	1	0	0	Drugs and targets
ASCORBIC ACID	CHEMBL196	Small molecule	Approval	ATC	1	0	0	Drugs and targets
AVACINCAPTAD PEGOL	CHEMBL6068573	Oligonucleotide	Approval	ATC	1	0	0	Drugs and targets
CENEGERMIN	CHEMBL4297852	Protein	Approval	ATC	1	0	0	Drugs and targets
CYSTEAMINE	CHEMBL602	Small molecule	Approval	ATC	1	0	0	Drugs and targets
DEXPANTHENOL	CHEMBL1200979	Small molecule	Approval	ATC	1	0	0	Drugs and targets
DIQUAFOSOL	CHEMBL221326	Small molecule	Approval	ATC	1	0	0	Drugs and targets

1 to 10 of 50

See all 50 drugs

Targets66

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
INSR	Insulin receptor	5	Insulin receptor agonist	Unknown	https://conductscience.org/library/genes/3643	Drugs and targets
GLP1R	Glucagon-like peptide 1 receptor	4	Glucagon-like peptide 1 receptor agonist	Unknown	https://conductscience.org/library/genes/2740	Drugs and targets
SLC5A2	Sodium/glucose cotransporter 2	4	Sodium/glucose cotransporter 2 inhibitor	Unknown	https://conductscience.org/library/genes/6524	Drugs and targets
ABCC8	Sulfonylurea receptor 1, Kir6.2	3	Sulfonylurea receptor 1, Kir6.2 blocker	Unknown	https://conductscience.org/library/genes/6833	Drugs and targets
DPP4	Dipeptidyl peptidase 4	3	Dipeptidyl peptidase IV inhibitor	Unknown	https://conductscience.org/library/genes/1803	Drugs and targets
KCNJ11	Sulfonylurea receptor 1, Kir6.2	3	Sulfonylurea receptor 1, Kir6.2 blocker	Unknown	https://conductscience.org/library/genes/3767	Drugs and targets
C3	Complement C3	1	Complement C3 inhibitor	Approval	https://conductscience.org/library/genes/718	Drugs and targets
CEP290	CEP290 mRNA	1	CEP290 mRNA positive modulator	Approval	https://conductscience.org/library/genes/80184	Drugs and targets
CHRNA4	Neuronal acetylcholine receptor; alpha4/beta2	1	Neuronal acetylcholine receptor; alpha4/beta2 agonist; Neuronal acetylcholine receptor; alpha4/beta2 partial agonist	Approval	https://conductscience.org/library/genes/1137	Drugs and targets
CHRNB2	Neuronal acetylcholine receptor; alpha4/beta2	1	Neuronal acetylcholine receptor; alpha4/beta2 agonist; Neuronal acetylcholine receptor; alpha4/beta2 partial agonist	Approval	https://conductscience.org/library/genes/1141	Drugs and targets

1 to 10 of 66

See all 66 targets

Trials4

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT04918823	Novel Use of Cyclosporine Ophthalmic Emulsion 0.05% in a PROSE Device	Phase 1/2	10	2025-01-13	Ocular Surface Disease	CYCLOSPORINE	Open Targets' reading of its record	ClinicalTrials.gov
NCT05161429	BESTMED: Observational Evaluation of Second Line Therapy Medications in Diabetes		550,000		Diabetes Mellitus, Type 2	ALOGLIPTIN, CANAGLIFLOZIN, DAPAGLIFLOZIN, DULAGLUTIDE, EMPAGLIFLOZIN, ERTUGLIFLOZIN, EXENATIDE, GLIMEPIRIDE, GLIPIZIDE, GLYBURIDE, INSULIN DETEMIR, INSULIN GLARGINE, LINAGLIPTIN, LIRAGLUTIDE, SAXAGLIPTIN, SEMAGLUTIDE, SITAGLIPTIN	Its record names the disease	ClinicalTrials.gov
NCT01823081	Combined Intravitreal Fasudil and Bevacizumab for Diabetic Macular Edema	Phase 3	74		Diabetic Macular Edema	BEVACIZUMAB, FASUDIL	Its record names the disease	ClinicalTrials.gov
NCT04735510	Novel Use of Restasis and PROSE Devices	Phase 3	0		Ocular Surface Disease	CYCLOSPORINE	Open Targets' reading of its record	ClinicalTrials.gov

Comparisons in its trials0

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

None in this release.

Papers from its trials0

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

None in this release.

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0005328

GET https://conductscience.org/api/diseases/v1/MONDO_0005328/drugs?page=2

API reference For AI assistants